Taking Wegovy and Cosentyx Together: What You Need to Know

You're on Cosentyx for a chronic condition, and weight is now part of the picture

Psoriasis, psoriatic arthritis and ankylosing spondylitis all carry an elevated risk of cardiovascular disease and metabolic complications, and excess weight makes several of these conditions harder to manage. So it's clinically logical, not just cosmetic, for someone on Cosentyx to consider a GLP-1 medicine like Wegovy. The biologics used in rheumatology and dermatology tend to be highly specific in how they work: secukinumab targets interleukin-17A, a protein involved in driving inflammation. Semaglutide, the active substance in Wegovy, acts on GLP-1 receptors in the gut and brain to reduce appetite and slow gastric emptying. These are different systems, and there is no documented pharmacokinetic interaction between the two medicines, meaning neither drug is expected to change how the other is absorbed, distributed, metabolised or eliminated.

That said, absence of a known interaction is not the same as a formal safety study comparing the two. Clinical trials for weight-loss medicines typically exclude participants on active immunosuppressants or complex biologics, which means robust head-to-head data on this specific combination simply doesn't exist yet. Your prescriber needs to know about both medicines and your full medical history before any decision is made. The NHS semaglutide medicines page sets out the types of medicines that require particular attention alongside semaglutide, including those affecting gastric absorption.

Practical considerations when both medicines are in play

Even without a direct drug-drug interaction, there are practical clinical factors to weigh. Wegovy slows gastric emptying, a known effect of GLP-1 receptor agonists. For most patients this is manageable, but it can theoretically affect the absorption timing of oral medicines taken alongside it. Cosentyx is given as a subcutaneous injection, so it bypasses the gut entirely; this particular concern doesn't apply. What does apply is the broader question of immune context. GLP-1 medicines have shown anti-inflammatory properties in some research settings, and weight reduction itself tends to reduce systemic inflammation over time, which may complement the goals of biologic treatment in some patients. But this is an emerging area of science, not a clinical recommendation.

Gastrointestinal side effects are the most common issue with semaglutide: nausea, loose stools, constipation and reflux are reported frequently, particularly in the early weeks of treatment. Anyone already managing a complex medical condition needs their prescriber to assess whether this is a sensible additional burden at this stage. The question of what ongoing support looks like during Wegovy treatment matters here, close monitoring from a clinical team, not a set-and-forget prescription, is appropriate in this situation.

Who should be involved in making this decision

This is a multi-prescriber question. The clinician managing your Cosentyx prescription (usually a rheumatologist or dermatologist) needs to know if you're starting a GLP-1 medicine. Equally, any clinician prescribing Wegovy should have sight of your full medication list, including immunosuppressants and biologics. Neither prescriber should be working blind to what the other has prescribed.

The licensed eligibility criteria for Wegovy are straightforward on paper: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as hypertension, type 2 diabetes or high cholesterol. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. But meeting those numbers doesn't automatically mean the timing and combination are right for you. A prescriber reviewing your case as a whole (including your Cosentyx) is the person who can make that call. You can read about how our clinical team approaches exactly this kind of assessment on the clinical team page.

It's also worth knowing that Wegovy is different from Ozempic, which is semaglutide licensed for type 2 diabetes rather than weight management; our page on semaglutide and Ozempic together covers that distinction if it's relevant to your situation. And if you're on or considering HRT alongside Wegovy, the interaction between HRT and Wegovy is worth reading too, given similar questions about concurrent specialist medicines arise there.

Starting Wegovy while on a biologic: what a cautious clinical process looks like

If a prescriber decides the combination is appropriate, the standard Wegovy titration schedule applies: starting at 0.25mg once weekly and increasing gradually (roughly every four weeks) under clinical oversight, up to the 2.4mg maintenance dose, or the recently approved 7.2mg dose for eligible patients. The early weeks at lower doses exist precisely to allow tolerability to be established. That's important for anyone carrying a more complex medical background, because it creates a structured opportunity to monitor for unexpected effects before the dose climbs.

Wegovy's UK approval (assessed by the MHRA and appraised by NICE in technology appraisal TA875) is for weight management specifically, with clinical oversight built into the recommendation. That oversight matters more, not less, when other specialist medicines are part of the picture. The semaglutide overview on this site covers the full mechanism and evidence base if you want to go deeper before speaking to a prescriber. The options for accessing Wegovy in the UK (NHS and private) are worth understanding too, alongside the new oral Wegovy tablet approved in June 2026, which removes the subcutaneous injection from the picture entirely and may be relevant for some patients.

If you're ready to find out whether Wegovy is clinically suitable given your current treatment, our prescribers review every consultation personally, a real clinician reads your answers, including your existing medication list. Check your eligibility with a free consultation.